Moyamoya in a child treated with interferon for recurrent osteosarcoma

J Pediatr Hematol Oncol. 2010 Aug;32(6):476-8. doi: 10.1097/MPH.0b013e3181e5e1db.

Abstract

Moyamoya is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of childhood cancer. We describe a 12-year-old female who developed moyamoya after the completion of systemic chemotherapy, surgery, and adjuvant interferon alpha for osteosarcoma with pulmonary metastases. Given the importance of characterizing late effects after the treatment of childhood cancer, the potential role of interferon alpha in the development of moyamoya is discussed.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Carotid Artery Diseases / chemically induced
  • Carotid Artery Diseases / pathology
  • Cerebral Arterial Diseases / chemically induced
  • Cerebral Arterial Diseases / pathology
  • Cerebral Infarction / chemically induced
  • Cerebral Infarction / pathology
  • Chemotherapy, Adjuvant / adverse effects
  • Child
  • Cisplatin / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Ifosfamide / administration & dosage
  • Interferon-alpha / adverse effects*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Magnetic Resonance Angiography
  • Methotrexate / administration & dosage
  • Moyamoya Disease / chemically induced*
  • Moyamoya Disease / pathology
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local / drug therapy*
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / secondary
  • Thyroiditis, Autoimmune / chemically induced

Substances

  • Antineoplastic Agents
  • Interferon-alpha
  • Etoposide
  • Doxorubicin
  • Cisplatin
  • Ifosfamide
  • Methotrexate